logo
EMA: Varicella Vaccines to Warn of Rare Encephalitis Risk

EMA: Varicella Vaccines to Warn of Rare Encephalitis Risk

Medscape14-07-2025
The European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has recommended an update to the product information of the varicella (chickenpox) vaccines Varilrix and Varivax to describe the severity of the risk for encephalitis. This follows a safety review prompted by a fatal case of encephalitis in a child in Poland after receiving Varilrix, a live-attenuated varicella vaccine.
The amended product information will provide more specific detail on encephalitis as a known adverse reaction to live-attenuated varicella vaccines, including acknowledgment of rare cases with fatal outcomes.
Patients and caregivers should be advised to seek immediate medical attention if symptoms suggestive of brain inflammation — such as persistent headache, altered mental status, or seizures — occur following vaccination.
The update serves as a reminder to assess patients thoroughly for any immunocompromising conditions prior to administering live vaccines. It also highlights the importance of postvaccination counseling.
The revised guidance will also extend to combination measles, mumps, rubella, and varicella (MMRV) vaccines such as Priorix-Tetra and ProQuad, which include the same live-attenuated varicella component. Updated product information will include more specific descriptions of encephalitis symptoms and timing, helping clinicians and patients recognize early warning signs and seek timely medical attention.
A 2024 case series spanning 15 years documented 20 instances of varicella vaccine-associated meningitis or encephalitis in immunocompetent children and adolescents. These cases, identified using cerebrospinal fluid PCR and metagenomic sequencing, underscore that serious neurologic events can occur but remain exceptionally rare.
A 22-year global review of live-attenuated varicella vaccine analyzed data from more than 212 million doses administered between 1995 and 2017, finding that common adverse events decreased over time — from approximately 500 reports per million doses (in 1995) to approximately 40 per million (in 2016). Serious adverse events were extremely rare, at 0.8 per million doses.
A recent Chinese postmarketing study involving more than 7.4 million administered doses reported that serious neurologic events represented only 0.51% of all adverse events following immunization, with no reported fatalities.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?

Yahoo

time2 hours ago

  • Yahoo

Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?

A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Yahoo

time5 hours ago

  • Yahoo

Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup

Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store